Orchestra BioMed Holdings, Inc. (OBIO) — Analyst outlook / Analyst consensus target is. Based on 4 analyst ratings, the consensus is bullish — 3 Buy, 1 Hold.
The consensus price target is $12.00, representing an upside of 162.6% from the current price $4.57.
Analysts estimate Earnings Per Share (EPS) of $-1.66 and revenue of $0.00B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-1.66 vs est $-1.66 (missed -0.2%). 2025: actual $-1.11 vs est $-1.74 (beat +36.3%). Analyst accuracy: 71%.
OBIO Stock — 12-Month Price Forecast
$12.00
▲ +162.58% Upside
Average Price Target
Based on 4 Wall Street analysts offering 12-month price targets for Orchestra BioMed Holdings, Inc., the price target is $12.00.
The average price target represents a +162.58% change from the last price of $4.57.
OBIO Analyst Ratings
Buy
Based on 4 analysts giving stock ratings to Orchestra BioMed Holdings, Inc. in the past 3 months
EPS Estimates — OBIO
71%
Analyst Accuracy
Fair
2 years compared
Actual vs Estimate
2024
Actual –$1.66
vs Est –$1.66
▼ 0.1% off
2025
Actual –$1.11
vs Est –$1.74
▲ 56.9% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Revenue Estimates — OBIO
44%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual $0.003B
vs Est $0.003B
▼ 21.7% off
2025
Actual $0.033B
vs Est $0.003B
▲ 89.6% off
Revenue Trend
Strong revenue growth over the period shown. Analysts forecast revenue contraction ahead.
